BioHistory Moment: Iditarod Trail used to transport diphtheria serum to Nome.

In 1925, a life-or-death race to save the children of Nome from a diphtheria epidemic made an international hero of one sled dog, and led to the creation of Alaska's Iditarod sled dog race. A diphtheria epidemic threatened remotely located Nome, and air transportation was unavailable to transport serum from Anchorage nearly a thousand miles away.

The solution: A relay of dog teams transported serum on the Iditarod Trail from Nenana to Nome, and every village enroute provided its best team and driver for the next leg continually moving the serum toward Nome. Gunnar Kaasen, a Norwegian musher, drove the final two legs into Nome behind his lead dog Balto through a blizzard with 80 mph winds to deliver 300,000 units of diphtheria antitoxin to Dr. Curtis Welch, the only doctor in Nome.

The serum arrived in time, prevented the epidemic and saved hundreds of lives. The 20 mushers had covered nearly 700 miles in slightly more than 127 hours in temperatures of minus40° Fahrenheit below zero and strong winds. The serum run received worldwide press coverage and the mushers received special gold medals and other recognition. In 1926, a statue of Balto, the heroic lead dog, was erected in New York's Central Park.

Learn about Seattle's PNDRI Life Sciences Incubator Building

Learn about biotechnology, medical device and pharmaceutical facilities available for sale, lease or sublease in Washington, regionally or nationwide.

Industry News...

Free News Release Posting & Archiving Service


• FDA's Black Box Warning addressed by Genelex's PlavitestT  The FDA added a new black box warning to Plavix, pointing out the importance of individual patient genetics in determining the effectiveness of Plavix treatment. The relabeling is in response to clinical research demonstrating that one-third of patients are in varying degrees of treatment failure.
  Genelex Corporation  March 12, 2010  
  
  
• Pfizer discontinues a Phase 3 study of figitumumab  Pfizer announced the discontinuation of A4021018 (also known as ADVIGO 1018), a Phase 3 trial examining the effects of investigational compound figitumumab (CP-751,871) in combination with erlotinib as a second/third-line treatment in patients with previously treated advanced NSCLC.
  Pfizer Inc.  March 11, 2010  
  
  
• Two Phase 3 trials of sunitinib did not meet the primary endpoint  Pfizer announced that two Phase 3 studies of Sutent(R) (sunitinib malate) in advanced breast cancer did not meet their primary endpoints.
  Pfizer Inc.  March 11, 2010  
  
  
• Cardiac Science announces Q4 and full year 2009 results  Revenue for the fourth quarter of 2009 was $42.2 million, down 17% from the fourth quarter of 2008, but up 8% sequentially from the third quarter of 2009. Revenue for 2009 was $156.8 million, down 24% from 2008.
  Cardiac Science Corporation  March 11, 2010  
  
  
• Abbott seeks FDA approval of a new six-month 45-mg formulation of Lupron(R) Depot  The U.S. Food and Drug Administration(FDA) has accepted for review the supplemental new drug application (sNDA) of a new six-month 45-mg formulation of Lupron(R) Depot (leuprolide acetate for depot suspension) for use in the palliative treatment of advanced prostate cancer.
  Abbott  March 11, 2010  
  
  

More... | Submit News Release | Advertising...

New Job Postings...

The Recruiter’s Studio: People, Careers, Conversations

• Senior Research Associate Dendreon Corporation (WA)
• Scientist II/SR Dendreon Corporation (WA)
• Research Scientist, Medicinal Chemistry Gilead Sciences (WA)
• Bioinformatics Scientist Institute for Systems Biology (WA)
• Director of Human Resources Institute for Systems Biology (WA)

More... | Job Advertising...

New Facilities Available...

ATC clean room constructors...validation guaranteed!

• 890 Embarcadero Road Property -- West Sacramento, CA
• CompleGen Lab/Office Space -- Seattle, WA
• Life Sciences Incubator -- Seattle, WA
• University of Iowa Oakdale Research Park Biotech Building -- Coralville, IA
• University of Iowa Oakdale Research Park BioVentures Center -- Coralville, IA

More... | Facility Advertising...

Upcoming Events...

• 03/12/2010: Are You Ready for the Changes to the Medical Device Directive
• 03/12/2010: Breakfast Buzz: The Good, the Bad and the Ugly
• 03/13/2010: Medical Devices and Pharmaceuticals: Great Opportunity and Great Challenges
• 03/15/2010: Pharmacovigilance
• 03/16/2010: ORCA Monthly Meeting: Requirements & Best Practices for Management Review (Part 3 of 4 in Medical Device Quality System Series)

More... | Submit Event | Event Advertising...